Nipro Of Japan To Begin Marketing Human iPS Cells To Drug Makers
This article was originally published in PharmAsia News
Executive SummaryJapan's Nipro says it plans to launch soon the nation's first sale of cultivated human stem cells to drug makers and research institutes. Nipro said sales should begin in June of cardiac muscle cells developed from human induced pluripotent stem cells. Similar cells from iPS cells in monkeys already are available on the market, but Nipro expects the human samples to enable assessments of drug side effects more readily, improving the speed and efficacy of clinical tests. The cells to be marketed as kits were produced by ReproCell, a Japanese biotech venture. (Click here for more - a subscription may be required
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.